Summary
Abbott Laboratories (ABT) has announced a significant leadership transition. Effective March 31, 2020, current CEO Miles D. White will step down from his CEO role and assume the position of Executive Chairman of the Board. Robert B. Ford, currently President and Chief Operating Officer, has been appointed as the new President and Chief Executive Officer and will join the Board of Directors immediately. This transition brings a seasoned leader, Robert B. Ford, into the CEO position, with a long history at Abbott in various key operational roles, most recently as President and COO. The appointment of an Executive Chairman in Miles D. White suggests a planned and structured succession, aiming to leverage his experience while facilitating the new CEO's leadership. Additionally, the company amended its bylaws to increase the size of its Board of Directors from fourteen to fifteen individuals, effective immediately.
Key Highlights
- 1CEO Miles D. White to step down as CEO on March 31, 2020, becoming Executive Chairman.
- 2Robert B. Ford appointed as the new President and CEO, effective March 31, 2020.
- 3Robert B. Ford appointed to Abbott's Board of Directors, effective immediately.
- 4Robert B. Ford has extensive experience within Abbott, holding various senior leadership roles since 1996.
- 5The Board of Directors has been increased in size from fourteen to fifteen members.
- 6The by-laws were amended to reflect the change in board size, effective November 12, 2019.